R&D | Cutting-edge science and innovative research

R&D

Beyond GLP-1: Preclinical hurdles and solutions for next-gen...

The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.

News

Alto raises $120m for resistant depression programme

Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.

News

BioMarin halts Voxzogo trials due to safety signal

BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug's label.

News

Roche's AI-powered digital pathology open environment in action

Roche accelerates AI adoption with NVIDIA deal

Roche has ramped up its investment in NVIDIA's AI chips, launching a hybrid-cloud AI factory that it believes is the largest in the pharma industry.

R&D

Women in life sciences: Why female representation still lags...

pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata, about being a woman in STEM.

News

Roche preps filings for new Ocrevus injection

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according

News

Consortium hunts new KRAS drugs with fruit flies and AI

The launch of the first drugs to inhibit the cancer-related protein KRAS was a milestone moment in oncology, but their efficacy wanes over time and tumours can develop res

R&D

Experts warn of superbug risks after Madonna’s hospitalisati...

The recent hospitalisation of Madonna once again highlights the risks posed by bacterial infections and their potentially serious consequences for patients.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Alto raises $120m for resistant depression programme

Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.

News

BioMarin halts Voxzogo trials due to safety signal

BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug's label.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Beyond GLP-1: Preclinical hurdles and solutions for next-gen...

The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.

R&D

Women in life sciences: Why female representation still lags...

pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata, about being a woman in STEM.

R&D

Changing Faces: Pharma and biotech, February 2026

The pharmaceutical and biotech sectors have seen a flurry of executive movement this month.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

R&D

pharmaphorum podcast Episode 248, Andrew Mackinnon, Medable

AI in clinical development & ‘white space’, with Andrew Mack...

Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.

R&D

JPM2026 wrap-up with Nicole Raleigh and Jonah Comstock

On JPM2026 and healthcare investment today, with Jonah Comst...

Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.

Video

R&D

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D